针对局部晚期食道状细胞癌的新辅助化疗免疫疗法:从文献综述和现实世界分析中获得的数据
Yao Zhang1,2, Huiting Li3, Bo Yu1,2
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Thoracic cancer
|March 27, 2024
概括
新辅助化疗免疫疗法 (NCIT) 对局部晚期食道状细胞癌 (ESCC) 是有前途的,提供生存益处和可接受的安全性. 需要进一步的第三阶段试验来证实这些发现,用于先进的ESCC治疗.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 新辅助化疗免疫疗法 (NCIT) 正在出现,用于局部晚期食道状细胞癌 (ESCC).
- 现有的关于NCIT在ESCC中的有效性和安全性的数据是有限的和不一致的.
- 现实世界的证据和元分析对于全面的评估至关重要.
研究的目的:
- 评估新辅助化疗免疫疗法 (NCIT) 在局部晚期食道状细胞癌 (ESCC) 患者的疗效和安全性.
- 将现实世界的数据与发表文献的元分析结果进行比较.
主要方法:
- 对128名接受NCIT和食道切除术的局部发达ESCC患者的回顾性分析.
- 评估病理反应 (pCR,MPR),生存率 (OS),反应率 (ORR,DCR),复发,R0切除和不良事件.
- 对27项涉及1734名患者的研究进行了元分析,以比较有效性和安全性数据.
主要成果:
- 现实世界中的队列:pCR 25%,MPR 46.1%,三年后的OS 64.8%,R0切除99.2%.
- 分析:聚合的PCR为29%,MPR为52%,ORR为71%,R0切除为98%,一年复发为12%.
- NCIT证明了可接受的安全性与可管理的治疗相关不良事件.
结论:
- 新辅助化疗免疫疗法 (NCIT) 是对局部晚期食道状细胞癌 (ESCC) 的安全和潜在有效治疗方法.
- 在ESCC中,NCIT提供了生存益处和有利的病理反应率.
- 高质量的随机第三期试验数据对于巩固NCIT在治疗高级ESCC中的作用至关重要.
相关概念视频
Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
162
Barrett Esophagus-II: Clinical Manifestations and Management
141
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
141


